BioPharma Dive May 28, 2024
After reporting positive clinical trial results for its drug brensocatib, Insmed plans to later this year file for U.S. approval in bronchiectasis that’s not associated with cystic fibrosis.
New Jersey-based drugmaker Insmed gained more than $3 billion in market value Tuesday after reporting clinical trial results for an experimental lung disease drug that impressed analysts.
Data from the trial, a Phase 3 study called Aspen, showed that Insmed’s drug can significantly ease the coughing and shortness of breath that people with bronchiectasis frequently experience. Compared to a placebo, treatment reduced the annualized rate of these so-called pulmonary exacerbations by one-fifth, while also keeping them at bay for longer.
Notably, the drug, brensocatib, wasn’t associated with substantially more side effects than...
Today's Sponsors
Today's Sponsor